000117605 001__ 117605
000117605 005__ 20230519145530.0
000117605 0247_ $$2doi$$a10.3390/biomedicines9121848
000117605 0248_ $$2sideral$$a126990
000117605 037__ $$aART-2021-126990
000117605 041__ $$aeng
000117605 100__ $$aQuero J.
000117605 245__ $$aGold(I) complexes bearing alkylated 1, 3, 5-triaza-7-phosphaadamantane ligands as thermoresponsive anticancer agents in human colon cells
000117605 260__ $$c2021
000117605 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117605 5203_ $$aOverheating can affect solubility or lipophilicity, among other properties, of some an-ticancer drugs. These temperature-dependent changes can improve efficiency and selectivity of the drugs, since they may affect their bioavailability, diffusion through cell membrane or activity. One recent approach to create thermosensitive molecules is the incorporation of fluorine atoms in the chemical structure, since fluor can tune some chemical properties such as binding affinity. Herein we report the anticancer effect of gold derivatives with phosphanes derived from 1, 3, 5-triaza-7-phosphaadamantane (PTA) with long hydrocarbon chains and the homologous fluorinated chains. Besides, we analysed the influence of temperature in the cytotoxic effect. The studied gold(I) complexes with phosphanes derived from PTA showed antiproliferative effect on human colon carcinoma cells (Caco-2/TC7 cell line), probably by inhibiting cellular TrxR causing a dysfunction in the intracellular redox state. In addition, the cell cycle was altered by the activation of p53, and the complexes produce apoptosis through mitochondrial depolarization and the consequent activation of caspase-3. Furthermore, the results suggest that this cytotoxic effect is enhanced by hyperthermia and the presence of polyfluorinated chains. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000117605 536__ $$9info:eu-repo/grantAgreement/ES/CIBERObn/CB06-03-1012$$9info:eu-repo/grantAgreement/ES/DGA-FSE/B16-20R$$9info:eu-repo/grantAgreement/ES/DGA-FSE/E07-20R$$9info:eu-repo/grantAgreement/ES/MCIU/RED2018-102471-T$$9info:eu-repo/grantAgreement/ES/MICINN-ISCIIII-FEDER/PID2019-104915RB-I00$$9info:eu-repo/grantAgreement/ES/MICINN/PID2019-104379RB-C21
000117605 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000117605 590__ $$a4.757$$b2021
000117605 592__ $$a0.874$$b2021
000117605 594__ $$a3.0$$b2021
000117605 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b121 / 297 = 0.407$$c2021$$dQ2$$eT2
000117605 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000117605 591__ $$aPHARMACOLOGY & PHARMACY$$b87 / 279 = 0.312$$c2021$$dQ2$$eT1
000117605 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2021$$dQ1
000117605 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b62 / 140 = 0.443$$c2021$$dQ2$$eT2
000117605 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117605 700__ $$aRuighi F.
000117605 700__ $$0(orcid)0000-0002-8251-8457$$aOsada J.$$uUniversidad de Zaragoza
000117605 700__ $$0(orcid)0000-0003-0553-0695$$aGimeno M.C.
000117605 700__ $$0(orcid)0000-0003-2457-3674$$aCerrada E.$$uUniversidad de Zaragoza
000117605 700__ $$0(orcid)0000-0002-3595-7668$$aRodriguez-Yoldi M.J.$$uUniversidad de Zaragoza
000117605 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica
000117605 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000117605 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000117605 773__ $$g9, 12 (2021), 1848$$tBiomedicines$$x2227-9059
000117605 8564_ $$s3352461$$uhttps://zaguan.unizar.es/record/117605/files/texto_completo.pdf$$yVersión publicada
000117605 8564_ $$s2780010$$uhttps://zaguan.unizar.es/record/117605/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117605 909CO $$ooai:zaguan.unizar.es:117605$$particulos$$pdriver
000117605 951__ $$a2023-05-18-15:30:01
000117605 980__ $$aARTICLE